Live Breaking News & Updates on Quality Cephalosporins

New Delhi [India], November 16 (ANI/PRNewswire): Orchid Pharma today announced their Q2'22 results. Fuelled by increasing sales and a laser-sharp focus on costs, Orchid Pharma reported a 36 per cent surge in total revenue from operations while the EBIDTA has jumped by 104 per cent over the quarter ending September 2021. Dhanuka Group, through its pharmaceutical arm, Dhanuka Laboratories Ltd, had taken over the company through the CIRP (Corporate Insolvency Resolution Process) on 31st March 2020. In spite of the COVID-19 Pandemic, the group through its relentless efforts has turned around the business and within a year made the loss-making business profitable. Speaking on the Q2 results, Manish Dhanuka, Managing Director, Orchid Pharma said, "Our revenues have seen a sharp uptick over the last one year. We have focussed on increasing the capacity utilizations while controlling costs. Owing to all the measures we took, bearing fruit, and a strong product pipeline, the results ar ....

New Delhi , Rajani Vickram , Manish Dhanuka , Indian Pharmaceutical Company , Orchid Pharma Ltd , Dhanuka Group , Dhanuka Laboratories Ltd , Orchid Pharma , Corporate Insolvency Resolution Process , Managing Director , Cephalosporin Antibiotics , New Chemical Entity , New Drug , Global Clinical Trials , New Drug Approval , Quality Cephalosporins , Sterile Products , Indian Bankruptcy Code , New Delhi India , Ovember 16 Ani Prnewswire Orchid Pharma Today Announced Their Q2 39 22 Results Fuelled By Increasing Sales Anda Laser Sharp Focus On Costs , Rchid Pharma Reporteda 36 Per Cent Surge In Total Revenue From Operations While The Ebidta Has Jumped By 104 Over Quarter Ending September 2021 Dhanuka Group , Hrough Its Pharmaceutical Arm , Dhanuka Laboratories Ltd , Ad Taken Over The Company Through Cirp Corporate Insolvency Resolution Process On 31st March 2020 In Spite Of Covid 19 Pandemic , He Group Through Its Relentless Efforts Has Turned Around The Business And Withina Year Made Loss Making Profitable Speaking On Q2 Results , Manish Dhanuka ,